Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.55 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25369647 | 1.00 | EGFR (0.60) | EGFRKDRERBB3DUS2 | |
| SCHEMBL25369410 | 0.92 | EGFR (0.58) | EGFRKDRERBB3DUS2 | |
| SCHEMBL30549068 | 0.92 | EGFR (0.58) | EGFRKDRERBB3DUS2 | |
| SCHEMBL25369408 | 0.92 | EGFR (0.58) | EGFRKDRERBB3DUS2 | |
| SCHEMBL25371196 | 0.90 | EGFR (0.57) | EGFRKDRERBB3DUS2 | |
| SCHEMBL25371195 | 0.90 | EGFR (0.57) | EGFRKDRERBB3DUS2 | |
| SCHEMBL25268967 | 0.90 | EGFR (0.59) | EGFRKDRERBB3DUS2 | |
| SCHEMBL25371616 | 0.90 | EGFR (0.59) | EGFRKDRERBB3DUS2 | |
| SCHEMBL26055536 | 0.90 | EGFR (0.58) | EGFRKDRERBB3DUS2 | |
| SCHEMBL25370183 | 0.86 | EGFR (0.57) | EGFRKDRERBB3DUS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | EGFR, WEE1, WEE2 | EGFR 1/4885KDR 33/4885ERBB3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.